Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Cyclophosphamide and Capecitabine in Pretreated HER2-negative Metastatic Breast Cancer
NCT01526512Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Dec 2011
- Primary completion
- Jul 2013
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, capecitabine in breast cancer, sponsored by Fudan University. Status: unknown.
02
Drugs
cyclophosphamidecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01526512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01526512.